Slama Cyril, Jerome Joëlle, Jacquot Christian, Bonan Brigitte
Pharmacy Department, European Hospital Georges Pompidou, Paris Cedex, France.
Pharm World Sci. 2005 Aug;27(4):339-43. doi: 10.1007/s11096-005-6034-x.
To quantify the amount of potential prescription errors for anticancer drugs in order to improve the quality of care.
The cytotoxic reconstitution unit at the Laennec Hospital in Paris, France during 6 months in the year 2000.
Pharmacist carried out a systematic analysis (e.g. dose, protocol, physicochemical properties) of the prescriptions for anticancer drugs (ACDs) before the compounding and handling at the cytotoxic unit of the pharmacy took place. The detected errors and potential errors were documented and analysed.
Numbers and kinds of medication errors.
Documenting data was difficult because of the inadequacy of existing classifications that usually do not include potential errors in prescriptions for with ACDs. Despite the presence of a formulary on the clinical wards, 349 errors were detected and documented, mainly concerning pharmaceutical aspects. Physicians were not aware of this type of errors due to lack of studies about their impact. Teaching aids such as a computer program for prescribing and production of ACDs could help in minimising these errors.
The 349 detected errors involved mainly the physicochemical properties of preparations. A computerised prescription network could possibly reduce the number of such errors. Furthermore, a redefinition of the classifications of errors for cytotoxic preparations seems desirable, and such classifications should include typical pharmaceutical problems, and potential errors that do not reach the patient.
量化抗癌药物潜在处方错误的数量，以提高医疗质量。
2000年期间，法国巴黎拉埃内克医院的细胞毒性药物调配单元，为期6个月。
在药房细胞毒性药物调配单元进行配药和处理之前，药剂师对抗癌药物（ACD）处方进行了系统分析（如剂量、方案、物理化学性质）。对检测到的错误和潜在错误进行记录和分析。
用药错误的数量和种类。
由于现有分类方法存在不足，通常不包括ACD处方中的潜在错误，因此记录数据较为困难。尽管临床病房有药品处方集，但仍检测并记录了349处错误，主要涉及药学方面。由于缺乏关于此类错误影响的研究，医生并未意识到这类错误。诸如用于ACD处方和生产的计算机程序等教学辅助工具有助于减少这些错误。
检测到的349处错误主要涉及制剂的物理化学性质。计算机化处方网络可能会减少此类错误的数量。此外，似乎有必要重新定义细胞毒性制剂的错误分类，此类分类应包括典型的药学问题以及未影响到患者的潜在错误。
